Merck's KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial - Argus Press

Merck's KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial  Argus Press

KENILWORTH, N.J.--(BUSINESS WIRE)--May 31, 2019--. Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the ...



Comments

Popular posts from this blog

How to perform chest auscultation and interpret the findings - Nursing Times

“National Day Awards 2019, Singapore News & Top Stories - The Straits Times” plus 1 more